Dr. Athene Lee is an Assistant Professor in the Department of Psychiatry and Human Behavior at Brown University Alpert Medical School. She is also a clinical neuropsychologist at the Butler Hospital Memory and Aging Program and the Director of the Butler Alzheimer’s Prevention Registry. Dr. Lee is a site principal investigator for the Trial-Ready Cohort for Preclinical/Prodromal AD (TRC-PAD), site neuropsychologist for the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER), and sub-investigator for several other Alzheimer’s disease clinical trials. At the Alzheimer’s Clinical Trial Consortium (ACTC), Dr. Lee serves as the founding Chair of the Early Career Project Evaluation Committee, a Co-Vice Chair of the Inclusion, Diversity and Education in Alzheimer’s disease – Clinical Trials (IDEA-CT) Committee, and the Butler Hospital Site Associate Principal Investigator. Dr. Lee received her doctoral degree in clinical psychology from Suffolk University and completed her residency and fellowship in neuropsychology at Brown University Alpert Medical School. She is dedicated to promoting early identification and intervention for cognitive decline and to enhance diverse representation in Alzheimer’s disease and related dementia research. Her research is focused on risk prediction algorithm for preclinical Alzheimer’s disease, disclosure of genetic and biomarker risk for Alzheimer’s disease, and cultural influence on subjective cognitive decline.
Jeremy Pizzola is the Director of the ACTC Administration Unit. The Admin Unit is responsible for decisions involving policy, priority of work, allocation of resources and personnel, and provides the necessary oversight to ensure adherence to applicable policies, regulations, and SOPs. The co-Director oversees essential components of the Admin Unit include Regulatory Affairs, Fiscal Managements, Contracts, Human Resources, and Quality Assurance (QA).
David S. Geldmacher, MD, FACP is Co-Chair of the ACTC Site Metrics and Study Budgets Committee (SBSMC) and a Site Member PI on the ACTC Steering Committee. He holds the Warren Family Endowed Chair in Neurology. He is Director of the Division of Memory Disorders and Behavioral Neurology at the University of Alabama at Birmingham. He serves as Medical Director for Neurology at the University of Alabama (UAB) Hospital. His research has centered on testing new dementia treatments and understanding the meaningfulness of treatment outcomes for affected people and their families. His other research interests include complex visual processing in aging and neurological conditions. Dr. Geldmacher is the author of Contemporary Diagnosis and Management of Alzheimer’s Dementia, and has published over 100 research articles, chapters, abstracts and reviews. He is a Fellow of both the American College of Physicians and the American Neurological Association. He has been elected as a member of the Alpha Omega Alpha medical honor society and has been listed in Best Doctors in America since 1998. Dr. Geldmacher graduated magna cum laude from the University of Rochester (New York) with his B.A. in Biology and Psychology. He obtained his M.D (with Certificate in Academic Research) from the State University of New York – Health Science Center at Syracuse. He trained in Neurology at Case Western Reserve University and completed a postdoctoral fellowship in Behavioral Neurology at the University of Florida.
Dr. Baker is co-chair of the ACTC Non-Pharmacological Interventions Committee, and leads the Inclusion/Diversity Committee of the Recruitment Unit. Dr. Baker is also lead co-Principal Investigator of U.S. POINTER, and co-PI of the U.S. POINTER Coordinating Center at Wake Forest School of Medicine. She is also PI, co-PI, or Project Director of three other large national studies focused on Alzheimer’s prevention, including the Women’s Health Initiative Sleep Hypoxia Effects on Resilience (WHISPER) study, the COcoa Supplement and Multivitamin Outcomes Study for the Mind (COSMOS-Mind), and Aerobic Exercise to Slow Cognitive Decline in Mild Cognitive Impairment (EXERT). She has held leadership positions for numerous NIH multi-site clinical studies (ADAPT, ADAPT-FS, Look AHEAD, WHIMS-ECHO, WHIMS-Y), and have been an investigator of over 50 clinical trials focused on aging, mild cognitive impairment and Alzheimer’s disease, which has resulted in over 75 first- or co-authored publications. She is Associate Director of the NIA Alzheimer’s Disease Core Center at Wake Forest School of Medicine, and Leader of the Center’s Outreach and Recruitment Core and Research Education Component Core. In addition to her research, her work also focuses on increasing racial and ethnic diversity in AD clinical studies, and recently served on the NIA/Alzheimer’s Association National taskforce to develop new strategies for recruitment and retention in Alzheimer prevention and treatment trials.
Jeffrey L. Cummings, MD, ScD, is Chair of the ACTC Neuropsychiatric Symptoms Committee. Dr. Cumming is Vice Chair of Research, UNLV Department of Brain Health. He is Founding Director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada, and Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Dr. Cummings is Principal Investigator/Director of the NIH/NIGMS-funded Center for Neurodegeneration and Translational Neuroscience. Dr. Cummings is a world-renowned Alzheimer’s researcher and leader of clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer’s disease through the Henderson Award of the American Geriatrics Society (2006), the Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association (2008), and the Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017). In 2010, he was honored by the American Association of Geriatric Psychiatry with their Distinguished Scientist Award. In 2018, he was honored with the Leadership and Achievement Award by the International Society of CNS Drug Development, and he received the Bengt Winblad Lifetime Achievement Award from the national Alzheimer’s Association. In 2019, the International Psychogeriatric Association awarded him with the Distinguished Service Award and he received the Alzheimer’s Drug Discovery Foundation’s Melvin R. Goodes Prize that honors an innovative researcher who has made a significant and lasting impact in the field. He was featured in the Gentleman’s Quarterly (June 2009) as a “Rock Star of Science™.” Dr. Cummings’ interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society. Dr. Cummings completed Neurology residency and a Fellowship in Behavioral Neurology at Boston University, Boston, Massachusetts. US training was followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London, England. Dr. Cummings was formerly Augustas Rose Professor of Neurology and Professor of Psychiatry at UCLA, Director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, and Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA. He is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association. Dr. Cummings has authored or edited 43 books and published over 750 peer-reviewed papers.
Dr. Gad Marshall is board certified in Neurology, and is the Associate Medical Director of Clinical Trials at the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital; Associate Neurologist at Brigham and Women’s Hospital; Assistant in Neurology at Massachusetts General Hospital; and Associate Professor of Neurology at Harvard Medical School. Dr. Marshall has served as site principal investigator for 13 Alzheimer’s disease clinical trials and 4 multicenter observational imaging biomarker studies, including currently the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) trial, the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 3, DoD-ADNI, and the Trial-Ready Cohort for Preclinical/Prodromal AD (TRC-PAD). He is the Brigham and Women’s Hospital Site Principal investigator, Steering Committee Member, and Chair of the Publications Committee for the Alzheimer’s Clinical Trial Consortium (ACTC). His research has focused on clinical correlates of instrumental activities of daily living and neuropsychiatric symptoms with amyloid, tau, and FDG PET, structural and resting-state functional MRI, and CSF biomarkers across the early Alzheimer’s disease spectrum.